台股 » 個股 » 逸達 » 籌碼相關 » 券商分點績效 » 券商分點個股進出

逸達

(6576)
  • 股價
    79.1
  • 漲跌
    --
  • 漲幅
    0.00%
  • 成交量
    32
  • 產業
    上櫃 生技醫療類股
  • 118人加入追蹤

    立即追蹤

  • 本地時間:13:30

     
逸達 (6576)籌碼相關-群益金鼎-高雄 券商分點個股進出
券商分點績效/獲利分析

透過統計各券商分點在長期買賣某個股的操作績效,來找出真正獲利的贏家所在券商分點,進而追蹤此贏家所操作的股票與軌跡。

Created with Highstock 1.3.7Zoom券商分點個股進出嗨投資 histock.tw05/0405/1806/0106/1406/2807/1207/2608/1008/2409/0609/2010/0410/1811/0211/1611/3012/1412/2801/1002/0402/1602/2603/1003/2004/0104/037577.58082.58587.5May '24Jul '24Sep '24Nov '24Jan '25Mar '2560d90dAll

群益金鼎-高雄 券商分點個股進出

日期買進張數買進均價賣出張數賣出均價收盤價買賣超60日均量成交佔比 大量交易提示
2025/03/280.481.3300.0081.600.42030.19%
2025/03/27082.4000.0083.0002030.00%
2025/03/26083.9000.0083.4002030.00%
2025/03/21083.0000.0083.9002090.00%
2025/03/18081.5000.0083.9001970.00%
2025/03/170.184.9500.0084.200.11970.06%
2025/03/14082.8000.0083.5002020.00%
2025/03/110.182.6000.0084.200.12030.05%
2025/03/0700.000.185.0084.60-0.1201-0.05%
2025/02/2500.000.185.7685.70-0.1232-0.04%
2025/02/190.386.5000.0086.000.32320.13%
2025/02/181.185.8000.0086.001.12290.48%
2025/01/02077.5000.0077.4001870.00%
2024/12/26177.60177.0077.8001830.00%
2024/12/18175.5000.0075.9011710.58%
2024/12/1000.00175.4073.40-1156-0.64%
2024/12/0300.00078.5078.300141-0.02%
2024/11/2900.003.277.8177.00-3.2133-2.41%
2024/11/2700.00078.4078.300126-0.01%
2024/11/210.379.0000.0079.400.31080.24%
2024/11/2000.00276.5076.80-2101-1.98%
2024/11/12276.1000.0076.0021071.87%
2024/11/0800.00279.2579.30-2107-1.86%
2024/11/07276.6000.0076.1021031.93%
2024/06/25180.90183.7083.5002600.00%
2024/06/24289.25188.5089.2012380.42%
2024/06/1300.00797.0097.00-7222-3.15%
2024/06/0700.00198.7099.60-1220-0.45%
2024/06/0400.00197.1095.80-1217-0.46%
2024/05/28295.8000.0095.9022390.84%
2024/05/27594.2000.0094.3052412.07%
2024/05/1300.00094.4394.1003240.00%
2024/05/1000.00094.3294.300324-0.01%
2024/05/02196.1000.0096.0013190.31%
2024/04/30195.9000.0095.9013190.31%
2024/04/11199.5000.0099.4013310.30%
2024/04/10199.501100.5099.4003300.00%
2024/04/0800.002100.2599.60-2329-0.61%
逸達兒童中樞性早熟三期臨床 三度獲DSMB正面回饋持續進行Anue鉅亨-2025/02/17
逸達受美國經銷商指示不定期出貨 1月營收年減逾6成Anue鉅亨-2025/02/08
逸達前列腺癌新劑型新藥 確立美國藥證審查完成目標日Anue鉅亨-2025/01/14
逸達 相關文章
逸達 相關影音
 
 
320小時35